Names
Blenrep Belantamab mafodotin-blmfIndications and usage
Belantamab mafodotin-blmf is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Side effects needing medical attention
Belantamab mafodotin-blmf can cause serious side effects, including:
- Eye problems. Eye problems are common with belantamab mafodotin-blmf and can also be severe. Belantamab mafodotin-blmf can cause changes to the surface of your eye, which can lead to symptoms of eye problems, including:
- decreased vision
- blurred vision
- dry eyes
- sensitivity to light o feeling like something is in your eyes
- eye irritation
- eye pain
- Ulcers on the surface of the eye (corneal ulcers), including with infection, may also happen during treatment.
The most common side effects of belantamab mafodotin-blmf when given with bortezomib and dexamethasone include:
- see “Eye problems” above
- upper respiratory tract infection
- liver problems
- diarrhea
- tiredness
- pneumonia
- cataract
- COVID-19
The most common severe abnormal blood test results during treatment with belantamab mafodotin-blmf include decreases in platelets, white blood cells, and hemoglobin, and increases in certain liver enzymes.